Medicus Fills Phase 2 Trial, Eyes FDA Talks for Needle-Free Skin Cancer
PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) said it has completed U.S. enrollment for a Phase 2 clinical study testing a needle-free treatment for a common form of skin …
Medicus Fills Phase 2 Trial, Eyes FDA Talks for Needle-Free Skin Cancer Read More